|
Workshop
Preclinical development & IND Filing: Nuts, Bolts and Best Practices
Speakers:
Tracy Chen, Jim Zhang, Peter Staehr, Anne Bonneville, Xingrong Liu
Organizers:
Tracy Chen, Shichang Miao
Date:
2018-01-22
Time:
8:30-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; For unemployed or students: $30; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(23)Absorption Systems; Applied StemCell Inc.; BRI Biopharmaceutical Research Inc.; Celerion; ChemPartner; Cyprotex; Cytovier LLC; Intertek; JOINN Labs; Lonza; MicroConstants; Mycenax; Pacific BioLabs; PHARMout Laboratories; Pion Inc.; QPS; Quotient Sciences; Sekisui XenoTech, LLC; SNBL USA; SOLVO Biotechnology; Spaulding Clinical Research; Worldwide Clinical Trials; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2018-01-21
(it will close sooner if the seating cap is reached)
About the Topic
Investigational new drug (IND) application is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations, and processes of assembling and filing an IND is the key to not only a successful filing but also a promising clinical development path forward. Often, there are cases where too many nice-to-have studies crowd in the package but critical studies/issues are not addressed, and this can lead to significant delays in clinical development. Additionally, the regulatory environment is changing as rapidly as the industry. Therefore, keeping up to date on the regulatory requirements and the industry’s best practices in different aspects including non-clinical safety, PK, CMC, and clinical plan is paramount.
In this workshop, our speakers highly experienced with IND filings will discuss systemically the preclinical studies required for small molecule IND filings and the nuts, bolts, and best practices for putting together a high-quality IND package, as well as how to interact with various regulatory agencies.
The following topics will be covered:
- Overview of preclinical development and IND filing - Various preclinical studies required (Safety, DMPK & CMC) - Clinical Development plans - Interfacing with regulatory agencies including FDA
Workshop Agenda:
8:45-9:15 PBSS Welcome and Introduction (Tracy Chen)
9:15-10:30 1. Chemistry, Manufacturing, and Controls (Jim Zhang)
10:30-10:40 Major Sponsor’s Presentation (Medpace)
10:40-10:55 Break
10:55-12:25 2. NonClinical Pharmacology & Pharmacokinetics (Xingrong Liu)
12:25-1:25 Lunch
1:25-3:25 3. Toxicology in Drug Development (Anne Killam Bonneville)
3:25-3:45 Break
3:45-3:55 Major Sponsor’s Presentation (Catalent)
3:55-5:00 4. Clinical Development Plan and Interaction with FDA (Peter Staehr)
5:00-5:30 Panel Discussion (All Speakers)
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Submit a Text Ad
|